Illuminating the immunological landscape: mitochondrial gene defects in pancreatic cancer through a multiomics lens

Front Immunol. 2024 Mar 6:15:1375143. doi: 10.3389/fimmu.2024.1375143. eCollection 2024.

Abstract

This comprehensive review delves into the complex interplay between mitochondrial gene defects and pancreatic cancer pathogenesis through a multiomics approach. By amalgamating data from genomic, transcriptomic, proteomic, and metabolomic studies, we dissected the mechanisms by which mitochondrial genetic variations dictate cancer progression. Emphasis has been placed on the roles of these genes in altering cellular metabolic processes, signal transduction pathways, and immune system interactions. We further explored how these findings could refine therapeutic interventions, with a particular focus on precision medicine applications. This analysis not only fills pivotal knowledge gaps about mitochondrial anomalies in pancreatic cancer but also paves the way for future investigations into personalized therapy options. This finding underscores the crucial nexus between mitochondrial genetics and oncological immunology, opening new avenues for targeted cancer treatment strategies.

Keywords: clinical application prospects; disease progression; immune escape; mitochondrial gene defects; multiomics analysis; pancreatic cancer.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genes, Mitochondrial
  • Genomics
  • Humans
  • Multiomics
  • Pancreatic Neoplasms* / therapy
  • Proteomics*

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Science and Technology Development Fund, Macau SAR (No.: 0098/2021/A2 and 0048/2023/AFJ), the National Natural Science Foundation of China (No.: 82361168663), and Macau University of Science and Technology’s Faculty Research Grant (No: FRG-23-003-FC).